Skip to main content

Perlegen Moves into a New Phase--and New Headquarters

SAN FRANCISCO, Jan. 10 - Perlegen Sciences' recent move to new facilities dovetails with the gene-to-phenotype association studies it is gearing up to begin, said Jesse Hsu, the company's director of corporate development.

 

In December the company moved from Santa Clara, Calif., into a 60,000-square-foot building in Mountain View, Calif. The new building has approximately half the space dedicated to a wet lab and the other half to computer facilities, Hsu told attendees of the 20th annual JPMorgan H&Q Healthcare Conference, which ends today.

 

The wet lab will be used over the next few months to begin DNA analysis of human blood samples for association studies that Perlegen has planned. The studies represent the second phase in the company's progression towards finding gene targets associated with disease, said Hsu. The first phase—haplotype mapping—will be finished around August, according to Hsu.

 

Hsu estimates the company will have its first gene targets toward the beginning of 2003. Perlegen plans to sell targets and to work to understand their biology to go further down the line towards drug development. "We have to eat while we grow," Hsu said.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.